FindTrial
Sign In

anti-CD33 CAR T cells

BIOLOGICAL2 trials

Sponsors

Chinese PLA General Hospital, iCell Gene Therapeutics

Conditions

Chemotherapy Refractory Adult Myeloid LeukemiaHigh Risk Hematologic MalignanciesRelapsed Adult Myeloid LeukemiaRelapsed and/or Refractory Acute Myeloid Leukemia

Phase 1

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
NCT01864902
Chinese PLA General HospitalChemotherapy Refractory Adult Myeloid Leukemia, Relapsed Adult Myeloid Leukemia
Start: 2013-04-30End: 2017-04-30Target: 10Updated: 2016-01-28
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
NCT05445765
iCell Gene TherapeuticsHigh Risk Hematologic Malignancies, Relapsed and/or Refractory Acute Myeloid Leukemia
Start: 2022-07-01End: 2024-06-30Target: 10Updated: 2022-07-06

Related Papers

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
Oncotarget2016-02-0516 citations
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Molecular Therapy2014-09-01404 citations